MECHANISM OF ACTION
By binding to soluble BLyS and reducing the autoreactive B cell population, belimumab decreases the production of autoantibodies.1,2
Patients on BENLYSTA experienced a 41% reduction in anti-double stranded DNA levels over 52 weeks.2
The clinical relevance of normalizing this biomarker has not been definitively established.
BENLYSTA selectively inhibits soluble BLyS, an important factor in SLE3-5
In many patients with SLE, higher concentration of BLyS promotes increased B-cell survival, including the survival of autoreactive B-cells.3
BENLYSTA is a targeted human monoclonal antibody that binds to soluble BLyS, inhibiting its binding to B-cell receptors.4
By reducing the autoreactive B-cell population, BENLYSTA decreases the production of autoantibodies.